PLOS ONE, an international, peer-reviewed journal publishes article of a malaria vaccine produced in ciliates
Leading journal presents a proof of principle study for Cilian’s expression technology CIPEXSystem to produce malaria vaccine candidates.
Münster, Germany, 30 January 2014, Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that PLOS ONE, the international, peer-reviewed, open-access, online publication journal, has published an article entitled: A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila.
PLOS ONE is run as a partnership between its in-house PLOS staff and international Advisory and Editorial Boards. PLOS (for Public Library of Science) is a non-profit organization of scientists and physicians committed to making the world’s scientific and medical literature a freely available public resource.
Münster, Germany, 30 January 2014, Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that PLOS ONE, the international, peer-reviewed, open-access, online publication journal, has published an article entitled: A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila.
PLOS ONE is run as a partnership between its in-house PLOS staff and international Advisory and Editorial Boards. PLOS (for Public Library of Science) is a non-profit organization of scientists and physicians committed to making the world’s scientific and medical literature a freely available public resource.